TICKERNERD
Menu
HCATHCATHealthcare · Health Information Services

HCAT Stock Forecast: Health Catalyst, Inc. Price Predictions for 2026-2027

Last close, 24 Sept 2026
$1.74
+1.16% on the day

The 6 Wall Street analysts covering Health Catalyst, Inc. hold a median 12-month price target of $1.9 — +9.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 23 Sept 2026 — in the lower half.

Market cap
$129.4M
Ticker Nerd rank
48 / 100
Median analyst target
$1.90
Analysts covering
6
Revenue$70.5M−12.7% y/y
Operating income−$9.4M
Net income−$40.5M
Free cash flow−$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.3%
1M
+9.4%
YTD
−27.2%
1Y
−39.2%
From 52W high
−49.7%
From 52W low
+74.7%
$1.00
$3.46
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HCAT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Health Catalyst, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
98
Size
73
Value
58
Issuance
53
Quality
45
Growth
38
Revisions
38
Momentum
29
Volatility
19

Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (19): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HCAT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HCAT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50$3.00$3.50Oct 25Jan 26Apr 26Jul 26HCATHigh $2.00Median $1.90Low $1.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
1 Buy5 Hold0 Sell
Low $1.50Median $1.90High $2.00

The green dot is the last close — the median target sits +9.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
21 Aug 2026Canaccord GenuityDowngradeHold$3.00 → $1.80
13 Aug 2026Wells FargoMaintainsEqual-Weight—
13 Aug 2026Wells FargoMaintainsEqual-Weight$1.75 → $1.50
11 Aug 2026CitigroupMaintainsNeutral—
11 Aug 2026CitigroupMaintainsNeutral$2.50 → $2.00
21 July 2026Canaccord GenuityMaintainsBuy$2.00 → $3.00
21 July 2026Canaccord GenuityMaintainsBuy—
26 June 2026Wells FargoMaintainsEqual-Weight$1.00 → $1.75
26 June 2026Wells FargoMaintainsEqual-Weight—
12 May 2026Stephens & Co.MaintainsEqual-Weight—
18 Mar 2026Wells FargoDowngradeEqual-Weight—
13 Mar 2026Canaccord GenuityMaintainsBuy—
13 Mar 2026Cantor FitzgeraldMaintainsNeutral—
13 Mar 2026CitigroupMaintainsNeutral—
13 Mar 2026Stephens & Co.MaintainsEqual-Weight—
13 Mar 2026StifelMaintainsHold—
9 Jan 2026CitigroupMaintainsNeutral—
11 Nov 2025CitigroupMaintainsNeutral—
11 Nov 2025StifelMaintainsHold—
11 Nov 2025Wells FargoMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HCAT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HCAT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, Health Catalyst, Inc. returned −39.2% against +17.3% for the S&P 500, dividends included.

HCAT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26HCATS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HCAT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−216.5%
Analysts raising
0
Analysts cutting
4
Fundamentals

Health Catalyst, Inc. (HCAT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
0.4×

Cheaper than 83% of US stocks

Price / book
1.3×

Cheaper than 61% of US stocks

EV / EBITDA
16.6×

Cheaper than 18% of US stocks

Growth & margins
Revenue growth (YoY)
−12.7%

Higher than 14% of US stocks

Earnings growth (YoY)
—
Gross margin
49.5%

Higher than 61% of US stocks

Operating margin
−5.3%

Higher than 27% of US stocks

Net margin
−90.6%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−118.1%

Higher than 12% of US stocks

Return on assets
−3.0%

Higher than 35% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Health Catalyst, Inc. (HCAT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Health Catalyst, Inc. has a market value of $129.4M and an enterprise value of $196.0M.

  • Revenue in the twelve months to 30 June 2026: $292.2M. The latest quarter shrank 12.7% year on year.

  • Net income over the same four quarters: −$264.8M, a −90.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.68.

  • Free cash flow in the twelve months to 30 June 2026: $6.6M, after $19.1M of capital spending.

  • Health Catalyst, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 74.6M.

  • Trailing P/E: −0.7×; forward P/E: 219.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Health Catalyst, Inc. employs 1,200 people — $244K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Sept 2026

Data provided by Twelve Data

Peers

HCAT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
HCATHealth Catalyst, Inc.$129.4M
48
OPRXOptimizeRx Corp.$141.1M
82
DHDefinitive Healthcare Corp.$144.1M
78
LFMDLifeMD, Inc.$146.8M
31
CCLDCareCloud, Inc.$87.5M
71
SPOKSpok Holdings, Inc.$214.2M
62
AMWLAmerican Well Corp.$218.6M
86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Health Catalyst, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HCAT news & analysis

Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 14 Sept 2026neutral

On September 14, 2026, Health Catalyst's Compensation Committee granted 2,747,385 restricted stock units to Simeon Kohl under the company's 2026 Employment Inducement Incentive Plan, in connection with his appointment as Chief Executive Officer and President effective that same day. The awards were granted as inducement material to Kohl's employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — The award marks the compensation package tied to the new CEO's appointment under Health Catalyst's leadership transition.

Health Catalyst Strengthens Its Board with the Appointment of Tami Reller

PRNewsWire · 14 Sept 2026neutral

Health Catalyst has appointed Tami Reller to its board of directors, effective October 1, 2026, as the company enters its next phase of growth. The appointment was announced in a September 14, 2026 press release.

Why it matters — HCAT watchers would care because the addition of a new board member signals governance changes during a defined growth phase for the company.

Health Catalyst Appoints Simeon Kohl as Chief Executive Officer and President

GlobeNewsWire · 8 Sept 2026neutral

Health Catalyst announced that Simeon Kohl has been appointed Chief Executive Officer, President, and a member of the Board of Directors, effective September 14, 2026. The appointment was announced on September 8, 2026.

Why it matters — A change in top leadership at Health Catalyst could signal a shift in the company's strategic direction for shareholders and industry observers.

Health Catalyst to Participate in Upcoming Investor Conference

GlobeNewsWire · 31 Aug 2026neutral

Health Catalyst announced that senior management members will participate in the 2026 Wells Fargo Healthcare Conference in Boston on September 9-10, 2026.

Why it matters — The participation offers HCAT watchers a public venue for management to present the company's outlook and engage with investors at a major industry conference.

Health Catalyst Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Health Catalyst reported second-quarter 2026 revenue above the high end of its guidance range and adjusted EBITDA at the high end of its outlook. The company also outlined a strategic shift following the July 31 divestiture of its Vitalware and Med-Metrix businesses.

Why it matters — The earnings results and post-divestiture strategic shift indicate how HCAT is positioned after reshaping its business portfolio.

FAQ

Frequently asked questions about HCAT stock

What is the HCAT stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Health Catalyst, Inc. have a median 12-month price target of $1.9, with estimates ranging from $1.5 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HCAT stock a buy right now?

Of the 6 analysts covering Health Catalyst, Inc., 1 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Health Catalyst, Inc. 48 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HCAT?

As at 23 Sept 2026, Health Catalyst, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).

Will HCAT stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +9.2% from the last close, and Ticker Nerd's factor model ranks Health Catalyst, Inc. 48 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HCAT stock forecast for 2030?

No analyst covering Health Catalyst, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HCAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $2 over the next 12 months.

How has HCAT stock performed over the past year?

Health Catalyst, Inc. returned -39.2% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Health Catalyst, Inc. do?

Health Catalyst, Inc. is a healthcare data and analytics technology company that provides software and services to healthcare organizations.

What is the latest news on HCAT?

The most recent item we track (GlobeNewsWire, 14 Sept 2026): "Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)". On September 14, 2026, Health Catalyst's Compensation Committee granted 2,747,385 restricted stock units to Simeon Kohl under the company's 2026 Employment Inducement Incentive Plan, in connection with his appointment as Chief Executive Officer and President effective that same day. The awards were granted as inducement material to Kohl's employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About Health Catalyst, Inc.

Health Catalyst, Inc. is a healthcare data and analytics technology company that provides software and services to healthcare organizations. Health Catalyst, Inc. focuses on helping hospitals, health systems, and other providers unify clinical, financial, and operational data through its analytics platform and related applications. Its offerings support areas such as quality improvement, population health, revenue cycle performance, and cost management, enabling organizations to turn fragmented information into actionable insights. The company also delivers professional services that help clients implement, configure, and use its technology more effectively. Health Catalyst, Inc. plays a role in the health information services market by supplying tools that support data-driven decision-making across the healthcare industry.

CEO Mr. Benjamin Albert · 1,200 employees · United States · https://www.healthcatalyst.com